Quantcast
Last updated on April 20, 2014 at 0:02 EDT

Latest Astex Stories

2013-10-09 20:22:20

GREENWICH, Conn., Oct. 9, 2013 /PRNewswire/ -- Sarissa Capital today issued the following open letter to shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX): Dear Fellow Shareholders, We recently learned that an Astex partnered cancer drug is about to enter Phase III clinical trials. LEE-011 is an orally available CDK4/6 inhibitor with potentially broad clinical application in the treatment of cancer that is being developed by Novartis in collaboration with Astex. On...

2013-10-09 16:24:18

GREENWICH, Conn., Oct. 9, 2013 /PRNewswire/ -- Sarissa Capital today issued the following open letter to shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX): Dear Fellow Shareholders, We recently learned that an Astex partnered cancer drug is about to enter Phase III clinical trials. LEE-011 is an orally available CDK4/6 inhibitor with potentially broad clinical application in the treatment of cancer that is being developed by Novartis in collaboration with Astex. On...

2013-10-02 12:29:29

Sarissa Capital will not tender at current price GREENWICH, Conn., Oct. 2, 2013 /PRNewswire/ -- Sarissa Capital issues the following letter regarding Astex Pharmaceuticals, Inc. (NASDAQ: ASTX): We are one of Astex's largest shareholders, owning approximately 5% of the outstanding shares of the company. We believe the recently announced merger transaction with Otsuka Pharmaceutical significantly undervalues Astex and therefore we do not intend to tender our shares. It seems clear...

2013-09-06 20:21:05

BALA CYNWYD, Pa., Sept. 6, 2013 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Astex Pharmaceuticals, Inc. ("Astex" or the "Company") (Nasdaq: ASTX) relating to the proposed acquisition by Otsuka Pharmaceutical Co., Ltd. ("Otsuka"). Click here to learn more about the investigation http://brodsky-smith.com/635-astx-astex-pharmaceuticals-inc.html, or call: 877-534-2590. There is no cost or...

2011-09-09 04:39:00

OXFORD, England, September 9, 2011 /PRNewswire/ -- PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector. Dr Fintan...

2011-06-06 13:50:00

NEW YORK June 6, 2011 /PRNewswire/ -- SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced their June 2nd RetailInvestorConferences.com presentation is available for on-demand viewing. LINK: www.retailinvestorconferences.com > Click the red "register/ watch event now" button. SuperGen's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual...

2011-05-26 14:00:00

NEW YORK, May 26, 2011 /PRNewswire/ -- SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., president and chief executive officer, will present at RetailInvestorConferences.com. DATE: June 2nd, 2011 TIME: 10:00AM EDT LINK: www.retailinvestorconferences.com> Click the red "register/ watch event now" button. This will be a live, interactive online event where...

2011-05-03 01:00:00

CAMBRIDGE, England, May 3, 2011 /PRNewswire-FirstCall/ -- Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009. Total milestone payments received under the collaboration have now reached GBP5.9 million. The milestones relate to the application of Astex's Pyramid(TM)...

2008-10-03 09:00:38

Research and Markets (http://www.researchandmarkets.com/research/ab4b51/whos_developing_w) has announced the addition of the "Who's Developing What in Global Biopharmaceuticals?" report to their offering. A critical assessment of 50 leading companies, their research, products, partners and performance. The biopharmaceutical R&D sector is taking an ever more important role in the minds of industry and investors. The potential to fundamentally alter treatment regimes and cure,...